drug
Rare Disease
Preclinicalupdated 5mo agoby Dawn Sea Therapeutics
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagOncology6 co-mentions · 2 sources
- tagRare Disease5 co-mentions · 5 sources
- tagPulmonology2 co-mentions · 2 sources
- tagNSCLC2 co-mentions · 2 sources
- drugSL-9012 co-mentions · 2 sources
- drugUndisclosed2 co-mentions · 2 sources
- companyStemline Therapeutics Inc2 co-mentions · 2 sources
- companyJohns Hopkins University1 co-mentions · 1 sources
all catalysts(2)
News(10)
- STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine marketVaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.stat · 2h ago
- Precision for All: Closing the gap between innovation and impactWhy diagnostic-driven therapies need a new commercialization model to reach more eligible patients.biopharma_dive · 5h ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…biospace · 9h ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…biospace · 9h ago
- Opinion: FDA must ensure American patients can access new and experimental drugsThe FDA has taken important steps through Operation TrialBlazer and stronger scrutiny of foreign clinical data, but more must be done to make the United States more competitive in attracting clinic…biospace · 10h ago
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week sho…biospace · 3d ago
- Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againDespite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…biospace · 3d ago
- US government launches AI-driven programs to overhaul clinical trialsAmid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and…biospace · 4d ago
- The race for access: How the FAIR Act could reclaim U.S. biotech leadershipIn this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to r…biospace · 4d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that